

## « More than 80 AAV-Based Gene Therapy Products at the Clinical Stage»

*An accurate overview of the landscape of AAV-based gene therapy clinical trials  
More than 80 products involved and more than 110 ongoing clinical trials.  
Ten therapeutic areas and 40 diseases targeted by 49 biotech, pharma companies  
and academic organisations.*

Paris/Marseille, France, Jun. 05, 2020 - [BioPharmAnalyses](#) and [OctopusyX BioConsulting](#) announced today the launch of their latest report:

### *«AAV-Based Gene Therapy Products: Ongoing Clinical Trials» - (June 2020)*

This report of more than 200 pages is a unique and exhaustive overview of **116 ongoing clinical trials evaluating safety and clinical efficacy of 81 AAV-based gene therapy products**. These gene therapies now target a growing number of diseases. At this time, AAV-based products are developed for the **treatment of 40 diseases in 10 therapeutic areas** including hematological diseases, inherited metabolic diseases, lysosomal diseases, neurological diseases, neurodegenerative diseases, neuromuscular diseases and ophthalmological diseases.

Each product, disease and trial mentioned has been highlighted with the most relevant and recent scientific publications and business informations selected by our experts (see [sample pages](#)). The report also presents a comprehensive series of schematics offering a global overview of this rapidly evolving and competitive field (number of trials by phase, number of products by phase, number of trials by therapeutic area, number of products by therapeutic area...). « *Based on our experience and background, we are both firmly convinced that this document is a decision-making tool for biopharma leaders, investors and institutionals* » said Anne-Lise BERTHIER, General Manager of *BioPharmAnalyses* and Olivier REVELANT, General Manager of *OctopusyX BioConsulting*.

*BioPharmAnalyses* and OctopusyX BioConsulting have also recently published a report on « **Gene Therapy Products in development** » (Updated November 2019). This recognized document demonstrates that **more than 580 gene therapy products are under development** in biotech and pharmaceutical companies for the treatment of more than 240 diseases. These data support the predominance of AAV-based vectors among the most advanced clinical programs. They also confirm that RNA-based approaches are a dynamic field. Several of the most major drug companies have now chosen to increase and to secure a strategic positioning in this highly-competitive area. ([Sample Pages](#))

**About *BioPharmAnalyses*:** *BioPharmAnalyses* is a news platform including databases for the tracking and the strategic monitoring in the biopharmaceutical area. *BioPharmAnalyses* also conducts relevant strategic reports at the forefront of competitive emerging areas in the field of human health. *BioPharmAnalyses* can answer any question on agreements, fundraisings, clinical studies, mergers and give concise overview on hot topics and trends in this dynamic area. The company is located in Paris area, France. See [BioPharmAnalyses](#)

**About OctopusyX Bioconsulting:** OctopusyX BioConsulting accompanies the development of new multi-faceted skills in the emerging fields of innovative biotherapies. OctopusyX Bioconsulting provides the framework and the tools to gain a better understanding of emerging and mature competitive health technologies. OctopusyX BioConsulting supports project leaders in their efforts to initiate and implement any strategic project. The company is based in Marseille, France and is a member of the [Eurobiomed Biocluster](#). See [OctopusyX BioConsulting](#)

**Contact:**

[BioPharmAnalyses](#)

40, rue du petit bois

78370 Plaisir

France

Phone: 33 (0)686 683 220

Contact: [alb@biopharmanalyses.fr/](mailto:alb@biopharmanalyses.fr/)

[OctopusyX BioConsulting](#)

Centre Atlas

24, avenue du Prado

13006 Marseille. France

Phone: 33 (0) 668 071 907

Contact: [olivier@octopusyx.fr](mailto:olivier@octopusyx.fr)